hyperuricemia
Information
- Disease name
- hyperuricemia
- Disease ID
- DOID:1920
- Description
- "An acquired metabolic disease that has_material_basis_in an abnormally high level of uric acid in the blood." [url:http\://en.wikipedia.org/wiki/Hyperuricemia]
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT05253833 | Active, not recruiting | Phase 2 | Phase 2 to Assess Efficacy and Safety in AR882 Alone or in Combination With Allopurinol in Patients With Tophaceous Gout | August 12, 2022 | August 2024 |
| NCT00186940 | Completed | Rasburicase Treatment for Chemotherapy or Malignancy-Induced Hyperuricemia in Asthma/Allergy Patients | March 2005 | February 2010 | |
| NCT00230178 | Completed | Phase 3 | Rasburicase Versus Allopurinol in Tumor Patients at Risk for Hyperuricemia and Tumor Lysis Syndrome | April 2004 | December 2007 |
| NCT00230217 | Completed | Phase 4 | Study of Rasburicase as Treatment or Prevention of Hyperuricemia Associated With Tumor Lysis Syndrome in Patients With Relapsed or Refractory Lymphoma, Leukemia, or Solid Tumor Malignancy | March 2004 | July 2006 |
| NCT00288158 | Completed | Phase 2 | Primary Prevention of Hypertension in Obese Adolescents | September 2008 | January 2011 |
| NCT00302653 | Completed | Phase 4 | Rasburicase in Tumor Lysis Syndrome | February 2006 | |
| NCT00422318 | Completed | Phase 4 | Treatment of Hyperuricemia in Patients With Heart Failure | January 2004 | December 2005 |
| NCT00563771 | Completed | Phase 4 | Rasburicase for Treatment of Hyperuricemia in Children and Adolescence Patients With Tumor Lysis Syndrome | March 2003 | January 2004 |
| NCT00631579 | Completed | Phase 2 | Rasburicase as a Uricolytic Therapy for Hyperuricemia in Patients With Leukemia or Lymphoma | April 2003 | June 2004 |
| NCT00174954 | Completed | Magnetic Resonance Imaging in Subjects With Gouty Tophi | March 2002 | January 2003 | |
| NCT00997542 | Completed | Phase 4 | Allopurinol in Chronic Heart Failure | ||
| NCT01052987 | Completed | Phase 2 | Study of Tranilast Alone or in Combination With Allopurinol in Subjects With Hyperuricemia | January 2010 | November 2010 |
| NCT01109121 | Completed | Phase 2 | Tranilast Plus Allopurinol in Patients With Moderate to Severe Gout (TAnGO) | June 2010 | January 2011 |
| NCT01265264 | Completed | Phase 2 | Study to Evaluate sUA Lowering Activity, Safety and Efficacy of Oral Ulodesine Added to Allopurinol | December 2010 | February 2013 |
| NCT01336686 | Completed | Phase 2 | Safety and Efficacy Study of MBX-102 in Treatment of Hyperuricemia in Patients With Gout | May 2011 | November 2011 |
| NCT01361646 | Completed | Phase 1 | Safety, Tolerability and Pharmacokinetic/Pharmacodynamic Characteristics of LC350189 | June 2011 | January 2013 |
| NCT01363869 | Completed | N/A | Effects of Green Tea on Level of Serum Uric Acid in Healthy Individuals | June 2011 | March 2013 |
| NCT01407874 | Completed | Phase 2 | A Randomized, Double-Blind, Dose-Response Study of the Safety and Uric Acid Effects of Oral Ulodesine Added to Allopurinol in Subjects With Gout and Concomitant Moderate Renal Insufficiency | September 2011 | July 2012 |
| NCT01416402 | Completed | Phase 2 | Open Label Safety/Efficacy Study of Arhalofenate in Combination With Febuxostat for Hyperuricemia in Gout Patients | August 2011 | October 2011 |
| NCT01532622 | Completed | N/A | Impact of Blueberries on Uric Acid and Quality of Life | January 2012 | October 2013 |
| NCT01830725 | Completed | Purine Metabolism Enzyme SNP to Uric Acid Production | December 2012 | June 2016 | |
| NCT01881919 | Completed | Early Phase 1 | Effect of Quercetin Supplements on Healthy Males: a Four-Week Randomized Cross-Over Trial | February 2013 | November 2014 |
| NCT01931527 | Completed | N/A | Effect of Reducing Uric Acid on Insulin Sensitivity and Oxidative Status | July 2006 | November 2012 |
| NCT02190786 | Completed | Phase 2 | Phase II Exploratory Clinical Study of KUX-1151 | ||
| NCT02213562 | Completed | N/A | Effect of Chrysanthemum Flower Oil and Its Dose-dependency on Hyperuricemia | July 2014 | March 2016 |
| NCT02252835 | Completed | Phase 2 | Evaluate the PK, PD, and Safety of Arhalofenate in Combination With Febuxostat for Hyperuricemia in Patients With Gout | August 2014 | December 2014 |
| NCT02290210 | Completed | Phase 2 | Phase 2 Study of URC102 to Assess the Efficacy and Safety in Gout Patients | July 24, 2014 | August 31, 2015 |
| NCT02338128 | Completed | The Cardiovascular Protective Effects of Febuxostat in Peritoneal Dialysis Patients | January 2015 | January 2018 | |
| NCT02338323 | Completed | N/A | Compare the Renal Protective Effects of Febuxostat and Benzbromarone | January 2015 | December 2018 |
| NCT02344862 | Completed | Phase 2 | Study of FYU-981 in Hyperuricemia With or Without Gout | January 2014 | September 2014 |
| NCT02416167 | Completed | Phase 2 | Study of FYU-981 in Hyperuricemia With or Without Gout | May 2015 | November 2016 |
| NCT02557126 | Completed | Phase 2 | Study of URC102 to Assess the Safety and Efficacy in Gout Patients | October 2015 | August 2016 |
| NCT02600780 | Completed | Phase 4 | Zurig (Febuxostat) 40mg Efficacy and Safety Trial | November 2013 | March 2015 |
| NCT02837198 | Completed | Phase 2 | Study of FYU-981 in Hyperuricemia (Effect on Two Hyperuricemic Types) | July 2016 | March 2018 |
| NCT02956278 | Completed | Phase 4 | The Effects of BCRP Q141K on Allopurinol Pharmacokinetics and Dynamics | November 2016 | March 2018 |
| NCT02959918 | Completed | Phase 2 | Multi-Dose Safety/Pharmacodynamic Study of SEL-212/SEL-037 in Subjects With Symptomatic Gout & Elevated Blood Uric Acid | October 2016 | January 2019 |
| NCT03118739 | Completed | Phase 2 | Intensive Uric Acid Lowering With Verinurad and Febuxostat in Patients With Albuminuria | May 18, 2017 | August 13, 2018 |
| NCT03149939 | Completed | N/A | Use of Febuxostat in Hyperuricemia Among Hemodialysis Patients | January 1, 2017 | May 1, 2017 |
| NCT03185793 | Completed | Phase 2 | Dose-finding and Safety Study of SHR4640 in Subjects With Hyperuricemia | July 20, 2017 | July 20, 2018 |
| NCT03211403 | Completed | Phase 1 | Multiple Doses Study of SHR4640 in Male Subjects With High Serum Uric Acid Level | July 4, 2017 | February 15, 2018 |
| NCT03569020 | Completed | N/A | The Diet Gout Trial | August 7, 2018 | July 23, 2019 |
| NCT03636529 | Completed | N/A | Tart Cherry Juice and Markers of Inflammation, CVD, and Diabetes | June 1, 2010 | May 31, 2011 |
| NCT03648996 | Completed | Phase 2 | Sex-related Differences in Arterial Stiffness in Type 2 Diabetics: Role of Uric Acid | November 1, 2018 | March 10, 2022 |
| NCT03906006 | Completed | Phase 1 | A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ABP-671 in Healthy Subjects | October 17, 2018 | June 20, 2019 |
| NCT03921736 | Completed | Phase 4 | Reversal of an Unfavorable Effect of Hydrochlorothiazide Compared to Angiotensin Converting Enzyme Inhibitor on Serum Uric Acid and Oxypurines Levels by Estrogen-progestin Therapy in Hypertensive Postmenopausal Women. | January 10, 2000 | November 17, 2005 |
| NCT03927677 | Completed | Phase 1 | The Effect of Colchicine on the Pharmacokinetic Profile of LC350189 in Healthy Aldults. | November 5, 2019 | November 26, 2019 |
| NCT03934099 | Completed | Phase 2 | A Study to Assess Efficay and Safety of LC350189 Different Doses in Gout Patients With Hyperuricemia | December 2, 2019 | May 17, 2021 |
| NCT04040816 | Completed | Phase 2 | Placebo Controlled, Multiple Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SAP-001 in Gout Patients | January 1, 2019 | August 30, 2020 |
| NCT04060173 | Completed | Phase 1 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ABP-671 | September 5, 2019 | February 7, 2020 |
| NCT04066712 | Completed | Phase 1 | Renal PK Study of LC350189 | November 19, 2019 | September 12, 2020 |
| NCT04070846 | Completed | Phase 1 | Mass Balance Study of [14C]LC350189 in Healthy Volunteers | February 26, 2020 | March 7, 2020 |
| NCT04139824 | Completed | Phase 1 | The Effect of Naproxen on the Pharmacokinetic Profile of LC350189 in Healthy Adults | January 22, 2020 | February 25, 2020 |
| NCT04144088 | Completed | Phase 2 | Traditional Chinese Medicine in the Treatment of Patients With Hyperuricemia. | June 1, 2006 | June 30, 2007 |
| NCT04161872 | Completed | Phase 4 | Nutraceutical on Hyperuricemia | October 1, 2018 | December 31, 2019 |
| NCT04165499 | Completed | Early Phase 1 | Effect of the Consumption of a Combination of Plant Extracts (BSL_EP026) on Serum Uric Acid. | November 11, 2019 | March 20, 2020 |
| NCT04236219 | Completed | Phase 1 | ALLN-346 Single Ascending Dose (SAD) Study in Healthy Volunteers | September 2, 2020 | November 6, 2020 |
| NCT04638543 | Completed | Phase 2 | A Study to Assess the Efficacy, Safety, and Pharmacokinetics of ABP-671 in Patients With Gout or Hyperuricemia | November 27, 2020 | October 26, 2021 |
| NCT04829435 | Completed | Phase 1 | Study 102: Multiple Ascending Dose Study of ALLN-346 (Engineered Urate Oxidase) | April 21, 2021 | June 1, 2021 |
| NCT04886050 | Completed | Phase 1 | Relative Bioavailability Study to Assess an LC350189 Tablet Compared to an LC350189 Capsule in Healthy Adults | July 31, 2021 | December 10, 2021 |
| NCT04938024 | Completed | N/A | Hmong Microbiome ANd Gout, Obesity, Vitamin C (HMANGO-C) | March 28, 2021 | August 30, 2023 |
| NCT04966325 | Completed | Early Phase 1 | Thorough QT (TQT) Study to Evaluate the Effect of LC350189 on Cardiac Repolarization in Healthy Male and Female Subjects | September 23, 2021 | December 7, 2021 |
| NCT04987242 | Completed | Phase 2 | An Inpatient Study of ALLN-346 (Engineered Urate Oxidase) in Hyperuricemic Subjects (Study 201) | July 16, 2021 | March 2, 2022 |
| NCT05119686 | Completed | Phase 2 | Phase 2b Evaluation of Efficacy and Safety of AR882 in Gout Patients | November 16, 2021 | November 17, 2022 |
| NCT05168683 | Completed | Phase 1 | Scintigraphy Study in Healthy Volunteers to Characterize the Performance of ALLN-346 Tablets | January 11, 2022 | February 23, 2022 |
| NCT05474560 | Completed | Phase 4 | Febuxostat Versus Allopurinol on Hepatic Steatosis in MAFLD Patients | January 1, 2022 | January 28, 2023 |
| NCT06168929 | Completed | Phase 1 | Bioequivalence Study of 2 Sizes of SHR4640 Tablets Orally in Healthy Subjects | December 13, 2023 | January 13, 2024 |
| NCT06189404 | Completed | Phase 1 | Effect of Tigulixostat on the Pharmacokinetics of Theophylline | October 31, 2023 | November 30, 2023 |
| NCT00741442 | Completed | Phase 2 | A Study of RDEA806 in Hyperuricemic Subjects With Symptomatic Gout | July 2008 | September 2009 |
| NCT00756964 | Completed | Phase 2 | Lowering Serum Uric Acid to Prevent Acute Kidney Injury | October 2008 | August 2011 |
| NCT00868673 | Completed | N/A | The Role Of Fructose and Uric Acid In the Development of Obesity and Metabolic Syndrome | March 2009 | February 2010 |
| NCT00919243 | Completed | Phase 4 | Prednisone for Heart Failure Patients With Hyperuricemia | February 2009 | August 2010 |
| NCT00921375 | Completed | Phase 3 | Safety and Efficacy of TULY (Rasburicase) in Prevention and Treatment of Malignancy-associated Hyperuricemia | February 2010 | January 2012 |
| NCT00955981 | Completed | Phase 2 | Gout Dose Response Study | July 2009 | September 2011 |
| NCT00978653 | Completed | N/A | The Effect of Uric Acid Decrement on Endothelial Function in Patients With Chronic Renal Failure | April 2008 | May 2009 |
| NCT00995618 | Completed | Phase 2 | Study of Tranilast Alone or in Combination With Febuxostat in Patients With Hyperuricemia | September 2009 | April 2010 |
| NCT06463561 | Not yet recruiting | Phase 4 | CPAP Effect on Lipid Profile and Hyperuricemia in Patients With Dyslipidemia and Moderate-severe Obstructive Sleep Apnea | June 20, 2024 | December 31, 2027 |
| NCT05913310 | Not yet recruiting | Phase 4 | Efficacy and Safety of Kui-Yuan Chewable Tablets in Patients With Hyperuricemia | July 2023 | August 2024 |
| NCT06310967 | Not yet recruiting | Phase 1/Phase 2 | A Dose Escalation Study of IG3018 in Subjects With Hyperuricemia With or Without Chronic Kidney Disease | March 2024 | June 2025 |
| NCT05586958 | Recruiting | Phase 3 | Tigulixostat, Phase 3 Study, Placebo Controlled in Gout Patients | October 25, 2022 | June 2025 |
| NCT06119802 | Recruiting | Prediction of UA/SOD Ratio as a Biomarker of Oxidative Stress in Atrial Fibrillation | January 1, 2022 | April 30, 2024 | |
| NCT06084585 | Recruiting | N/A | The Efficacy of Amway Uric Acid Lowering Product on Hyperuricemia | October 23, 2023 | March 15, 2024 |
| NCT06439602 | Recruiting | Phase 3 | Phase 3 Evaluation of Efficacy and Safety of AR882 in Gout Patients | June 2024 | November 2026 |
| NCT03899883 | Recruiting | Phase 2 | Uric Acid Lowering Trial in Youth Onset T2D | January 1, 2020 | June 30, 2023 |
| NCT06315543 | Recruiting | N/A | Effect of Increased Daily Water Intake in Patients With Hyperuricemia | May 23, 2024 | November 1, 2024 |
| NCT06056570 | Recruiting | Phase 1/Phase 2 | Open Label PK, PD and DDI of Dotinurad and Allopurinol in Gout Patients With Hyperuricemia | October 2023 | November 2023 |
| NCT04801745 | Recruiting | N/A | Vegan Diet, Amla Fruits and Uric Acid | March 20, 2021 | June 30, 2024 |
| NCT04733079 | Recruiting | N/A | Treat-to-target by Email During Urate-lowering Therapy in Gout | December 15, 2021 | October 1, 2024 |
| NCT05954169 | Recruiting | Phase 1 | Pharmacokinetic/Pharmacokinetic and Safety Studies of SHR4640 in Subjects With Moderate Renal Insufficiency and Healthy Subjects | August 7, 2023 | November 10, 2023 |
| NCT04463940 | Recruiting | Xanthine Oxidase and Uric Acid Origin in Preeclamptic Women | June 30, 2020 | August 2024 | |
| NCT05434858 | Recruiting | N/A | Imagery as Biomarker of Gout | September 9, 2022 | September 9, 2029 |
| NCT06315569 | Recruiting | N/A | The Effect of Exercise at Different Time Intervals on Hyperuricemia | May 24, 2024 | November 1, 2024 |
| NCT05476627 | Recruiting | Risk Factors and Multiomics Study of Chronic Kidney Disease Caused by Metabolic Diseases | July 1, 2022 | July 1, 2027 | |
| NCT04399915 | Recruiting | Effect of Oxalate and Urate Metabolism on CKD Evolution | January 10, 2019 | December 2024 | |
| NCT04199325 | Recruiting | N/A | Probiotics for Gout / Hyperuricemia: A Randomized, Intervention, Parallel Controlled, Multicenter Clinical Trial | November 1, 2018 | March 2024 |
| NCT05504083 | Recruiting | Phase 2 | Evaluate the Efficacy and Safety of D-0120 in Primary Hyperuricemia Patients | September 28, 2022 | April 26, 2024 |
| NCT05574036 | Recruiting | Phase 2 | Comparative Study Between Febuxostat Versus Vitamin E in Non-alcoholic Steatohepatitis Patients With Hyperuricemia | August 25, 2022 | December 25, 2024 |
| NCT05586971 | Recruiting | Phase 3 | Tigulixostat, Phase 3 Study, Allopurinol Controlled in Gout Patients | March 30, 2023 | December 2025 |
| NCT03495999 | Terminated | Hyperuricemia and Left Ventricular Diastolic Function | August 1, 2017 | April 3, 2018 | |
| NCT04987294 | Terminated | Phase 2 | Phase IIa Study of ALLN-346 (Engineered Urate Oxidase) in Subjects With Hyperuricemia, Gout and Chronic Kidney Disease | September 2, 2022 | September 2, 2022 |
| NCT03865407 | Terminated | Phase 2 | Uric Acid Reduction as a Novel Treatment for Pediatric Chronic Kidney Disease | March 10, 2019 | October 7, 2020 |
| NCT00607152 | Terminated | Phase 3 | Rasburicase (Fasturtec) Registration Trial | October 2007 | January 2009 |
| NCT02462421 | Terminated | Phase 4 | Pharmacogenetics of SGLT2 Inhibitors | June 1, 2015 | December 31, 2021 |
| NCT00664144 | Terminated | Phase 2 | Rasburicase for the Treatment/Prevention of Hyperuricemia in Adult Patients With Relapsing Aggressive Non Hodgkin's Lymphoma | July 2002 | January 2005 |
| NCT02008968 | Unknown status | N/A | Effect of Allopurinol Treatment on Insulin Resistance | December 2013 | August 2014 |
| NCT04180982 | Unknown status | Phase 2 | A Safety and Efficacy Study of SHR4640 and Febuxostat in Subjects With Hyperuricemia | December 3, 2019 | August 30, 2020 |
| NCT01818505 | Unknown status | The Influence of Antiphospholipid Antibodies on the Relationship Between Hyperurecemia, Gout and Metabolic Syndrome | March 2013 | ||
| NCT02282683 | Unknown status | Phase 2/Phase 3 | Long-term Prednisone Use for End-stage Heart Failure | December 2013 | December 2017 |
| NCT01519687 | Unknown status | Phase 2 | Study of Levotofisopam 50 mg Three Times a Day (TID) Administered for 7 Days on Hyperuricemia and Gout | January 2012 | June 2012 |
| NCT04352153 | Unknown status | N/A | Role of Uralyt-U in Patients With Hyperuricemia | April 1, 2020 | October 31, 2020 |
| NCT01984749 | Unknown status | N/A | Febuxostat for Cerebral and caRdiorenovascular Events prEvEntion stuDy | November 2013 | |
| NCT04157959 | Unknown status | Phase 1 | The Drug-Drug Interaction of SHR4640 and Febuxostat in Patients With Hyperuricemia | October 14, 2019 | June 30, 2020 |
| NCT04012294 | Unknown status | Phase 3 | Effects of Allopurinol on Inflammation and Ultrasonographic Changes in People With Elevated Uric Acid But no Symptoms | August 30, 2019 | February 28, 2021 |
| NCT04586803 | Unknown status | Phase 1 | Study on the Bioavailability of Three Different Prescription Processes of SHR4640 Tablets in Healthy Volunteers | October 2020 | December 2020 |
| NCT03473951 | Unknown status | The Relationship Among, Serum Uric Acid, Left Ventricular Hypertrophy and Metabolic Syndrome | March 26, 2018 | December 2020 | |
| NCT02502565 | Unknown status | Musculoskeletal Ultrasound in Asymptomatic Hyperuricemia | January 2012 | March 2019 | |
| NCT04622124 | Unknown status | Phase 1 | A Safety and Tolerability Study of FCN-207 in Healthy Volunteers | November 11, 2020 | June 7, 2022 |
| NCT05245890 | Unknown status | Assocaiton Between Uric Acid Trajecteries and Remission of NAFLD in NAFLD Individuals | March 1, 2022 | March 1, 2024 | |
| NCT05226013 | Unknown status | Phase 1 | Tolerance, Pharmacokinetics / Pharmacodynamics (PK / PD) and Immunogenicity of Pegylated Uric Acid Oxidase for Injection in Healthy Adults and Hyperuricemia Volunteers | December 8, 2021 | April 1, 2023 |
| NCT02891031 | Unknown status | N/A | The Effects of Rhus Coriaria L. on Serum Uric Acid Levels | June 1, 2019 | December 1, 2019 |
| NCT02944214 | Unknown status | N/A | Compare the Renal Protective Effects of Febuxostat and Benzbromarone in CKD Chinese Patients | October 2016 | December 2019 |
| NCT04799925 | Unknown status | Hyperuricemia and Diabetic Nephropathy | April 15, 2021 | December 30, 2022 | |
| NCT01038947 | Unknown status | Phase 1 | Safety and Efficacy Study of Intramuscular Uricase-PEG 20 | December 2009 | May 2010 |
| NCT01021241 | Unknown status | Phase 1 | Safety and Efficacy Study of Intravenous Uricase-PEG 20 | October 2009 | March 2010 |
| NCT03691688 | Unknown status | The Long Term Effect of Low Dose Aspirin on Uric Acid in Chinese Patients With Coronary Artery Disease（AURORA） | December 1, 2018 | March 1, 2022 | |
| NCT03534037 | Unknown status | Phase 4 | Urate Lowering Therapies and Left Ventricular Diastolic Dysfunction | February 1, 2020 | December 2021 |
| NCT03200210 | Unknown status | Phase 4 | Lowering-hyperuricemia Treatment on Cardiovascular Outcomes in Peritoneal Dialysis Patients | July 11, 2017 | December 31, 2022 |
| NCT04953533 | Unknown status | Research and Development of a New Technology for Detection of Abnormal Excretion of Intestinal Uric Acid Involved in the Incidence of Gout | July 6, 2021 | December 31, 2023 | |
| NCT03218709 | Unknown status | Phase 4 | The Intervention of Multi-vitamin With Minerals to Hyperuricemia | January 2017 | April 2018 |
| NCT03425708 | Unknown status | Phase 4 | Effect of Hyperuricaemia on Chronic Renal Disease | January 1, 2017 | December 31, 2018 |
| NCT03473444 | Unknown status | Prevalence of Hyperuricemia in Pakistan | March 1, 2018 | April 15, 2018 | |
| NCT04072471 | Withdrawn | Post-Authorisation Safety Study of Lesinurad | January 29, 2021 | June 30, 2023 | |
| NCT03076684 | Withdrawn | Early Phase 1 | Gender Differences in the Metabolic Effects of Uric Acid | March 3, 2017 | March 13, 2019 |
- Disase is a (Disease Ontology)
- DOID:0060158
- Cross Reference ID (Disease Ontology)
- MESH:D033461
- Cross Reference ID (Disease Ontology)
- NCI:C3961
- Cross Reference ID (Disease Ontology)
- SNOMEDCT_US_2023_03_01:271198001
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C0740394
- Exact Synonym (Disease Ontology)
- Blood urate raized
- Exact Synonym (Disease Ontology)
- uricacidemia
- HPO Human Phenotype ID (Human Phenotype Ontology)
- HP:0002149
- MedGen concept unique identifier (MedGen Concept name)
- C0740394
- MedGen unique identifier (MedGen Concept name)
- 149260
- MeSH unique ID (MeSH (Medical Subject Headings))
- D033461